ReviewMolecular biology reports2026
Platelet activation and eicosanoid signaling in ovarian cancer: implications for biomarker development.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ovarian cancer remains one of the most lethal gynecological malignancies worldwide due to late-stage diagnosis, poor prognosis, and frequent chemoresistance. The limited sensitivity and specificity of current diagnostic approaches, particularly for early-stage disease, highlight the urgent need for improved biomarkers and diagnostic strategies. Nowadays, ovarian cancer diagnostics are based mainly on the established biomarkers CA125 and HE4, which in some countries most commonly combined in the Risk of Ovarian Malignancy Algorithm (ROMA). Despite their widespread clinical use, these biomarkers are of limited specificity and sensitivity, particularly in early-stage disease, underscoring the need for more efficient screening and diagnostic approaches. This review summarizes current evidence on the molecular mechanisms linking oxidative stress, inflammation, and platelet activation with ovarian cancer progression and discusses the diagnostic and prognostic potential of related biomarkers. Oxidative stress and inflammation contribute to dysregulated signaling pathways and tumor progression, providing a mechanistic basis for the identification of novel biomarkers. Increasing evidence indicates that platelet activation contributes to tumor growth, angiogenesis, and metastasis. This justifies the strategy of exploring platelet-derived mediators, including thromboxane B
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.